24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC

Part of paid clinical trials in Lebanon, New Hampshire.

Sponsor
Dartmouth-Hitchcock Medical Center
Study ID
NCT07043270
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Pancreas Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nab-paclitaxel + Gemcitabine — DRUG
    Administered ion days 1, 8 and 15 of cycles 1 and 3 (28-day cycles).
  • modified FOLFIRINOX (mFOLFIRINOX) — DRUG
    Administered ion days 1 and 15 of cycles 2 and 4 (28-day cycles).

Study Details

The purpose of this research is to study the effects and safety of alternating neoadjuvant chemotherapy on borderline resectable pancreatic cancer.

Key Dates

Start date
Sep 29, 2025
Status verified
May 2025
Primary completion
Jul 1, 2028
Completion
Jul 1, 2029

Study Design

Enrollment
35 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment with Gemcitabine plus Nab-Paclitaxel and mFOLFIRINOX
    Patient has been diagnosed with borderline resectable pancreatic ductal adenocarcinoma (pancreatic cancer) and has not received systemic or radiation therapy. Treating physician has recommended neoadjuvant (pre-operative) chemotherapy and radiation, prior to surgery.

Primary Outcome Measure

One-year event-free survival (1y-EFS) [ Time Frame: I year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Dartmouth-Hitchcock Medical CenterLebanonNew Hampshire03756-

Find similar trials in Lebanon, NH

By research site
Dartmouth-Hitchcock Medical Center· Lebanon, NH

Related Studies